



Life's end Benefits of cannaBidiol (CBD) and tetrahyDrocannabinol (THC)

Providing hope for a potentially safe and effective **treatment** at the **end of life** for people with **agitation** related to **dementia**.


What is the LiBBY Study?

The **Life's-end Benefits of cannaBidiol and tetrahyDrocannabinol (LiBBY)** Study is the first of its kind to examine **possible benefits** of Delta-9-tetrahydrcannabinol (THC) and cannabidiol (CBD) as a safe treatment option for **hospice-eligible people** with agitation and any type of dementia. The LiBBY Study has sites across the United States.

Who is eligible?

- ❖ Dementia diagnosis
- ❖ Adults, age 40 or older
- ❖ Experiencing agitation
- ❖ In hospice or hospice eligible
- ❖ Have a study/care partner

Scan me!



Visit LibbyStudy.org or
call 1-800-LiBBY-11

Contact your nearest study site



The University of Maryland, Baltimore
Dr. Raya Kheirbek
Gerontology, Geriatrics & Palliative Medicine Division
22 S Greene St. Baltimore, MD 21201
(410)328-7849
LiBBY@som.umaryland.edu



Funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). Led by Alzheimer's disease research experts at the NIH-funded Alzheimer's Clinical Trials Consortium (ACTC).